Literature DB >> 33178421

The intervention of valproic acid on the tumorigenesis induced by an environmental carcinogen of PAHs.

Junxuan Peng1, Zuchao Cai1, Ruixue Zhao1, Jiahao Chen1, Guochao Liu1, Chao Dong1, David Lim2, Zhihui Feng1.   

Abstract

This study investigated whether valproic acid (VPA, a histone deacetylase inhibitor) can interfere with the carcinogenicity of polycyclic aromatic hydrocarbons (PAHs). A typical representative compound of PAHs, 7,12-Dimethylbenz[a]anthracene (DMBA), was used to induce rat breast cancer. The results showed that therapeutic concentration of VPA (50 and 100 mg/kg) delayed the occurrence of tumors, reduced tumor formation rate and attenuated tumors growth, and have a protective effect on normal tissues. The macrophage-mediated inflammatory response was found to be associated with the observed effect of VPA. In addition, we screened and validated a possible gene, Sema3c, which was involved in DMBA-induced breast cancer development and can be inhibited by VPA.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  DMBA; Sema3c; breast tumor; macrophage; valproic acid (VPA)

Year:  2020        PMID: 33178421      PMCID: PMC7640934          DOI: 10.1093/toxres/tfaa069

Source DB:  PubMed          Journal:  Toxicol Res (Camb)        ISSN: 2045-452X            Impact factor:   3.524


  44 in total

Review 1.  Class 3 semaphorin in angiogenesis and lymphangiogenesis.

Authors:  Federico Bussolino; Enrico Giraudo; Guido Serini
Journal:  Chem Immunol Allergy       Date:  2013-10-17

Review 2.  F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen.

Authors:  Alexandra Dos Anjos Cassado
Journal:  Results Probl Cell Differ       Date:  2017

3.  Graviola attenuates DMBA-induced breast cancer possibly through augmenting apoptosis and antioxidant pathway and downregulating estrogen receptors.

Authors:  Mohamed M Zeweil; Kadry M Sadek; Nabil M Taha; Yasser El-Sayed; Sherif Menshawy
Journal:  Environ Sci Pollut Res Int       Date:  2019-03-29       Impact factor: 4.223

4.  Rad52 inactivation is synthetically lethal with BRCA2 deficiency.

Authors:  Zhihui Feng; Shaun P Scott; Wendy Bussen; Girdhar G Sharma; Gongshe Guo; Tej K Pandita; Simon N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-08       Impact factor: 11.205

5.  Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors.

Authors:  Irmgard Costa; Montserrat Solanas; Eduard Escrich
Journal:  Arch Pathol Lab Med       Date:  2002-08       Impact factor: 5.534

Review 6.  The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.

Authors:  Naomi L Sharma; Blaz Groselj; Freddie C Hamdy; Anne E Kiltie
Journal:  BJU Int       Date:  2013-04       Impact factor: 5.588

7.  Establishment of novel rat models for premalignant breast disease.

Authors:  Feng Wang; Zhongbing Ma; Fei Wang; Qinye Fu; Yunzhi Fang; Qiang Zhang; Dezong Gao; Yuyang Li; Liang Li; Lixiang Yu; Zhigang Yu
Journal:  Chin Med J (Engl)       Date:  2014       Impact factor: 2.628

8.  ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer.

Authors:  Steffen Heeg; Koushik K Das; Maximilian Reichert; Basil Bakir; Shigetsugu Takano; Julia Caspers; Nicole M Aiello; Katherine Wu; Albrecht Neesse; Anirban Maitra; Christine A Iacobuzio-Donahue; Philip Hicks; Anil K Rustgi
Journal:  Gastroenterology       Date:  2016-06-16       Impact factor: 22.682

9.  Silencing of cadherin-17 enhances apoptosis and inhibits autophagy in colorectal cancer cells.

Authors:  Xia Tian; Zheng Han; Qingxi Zhu; Jie Tan; Weijie Liu; Yanfen Wang; Wei Chen; Yanli Zou; Yishan Cai; Shasha Huang; Aifang Chen; Ting Zhan; Min Huang; Meng Liu; Xiaodong Huang
Journal:  Biomed Pharmacother       Date:  2018-09-15       Impact factor: 6.529

10.  Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation.

Authors:  Jeong Il Yu; Changhoon Choi; Sung-Won Shin; Arang Son; Ga-Haeng Lee; Shin-Yeong Kim; Hee Chul Park
Journal:  Sci Rep       Date:  2017-11-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.